Phaseline

Targets › OXTR

OXTR (Oxytocin receptor): drug programs, companies and trials

8 programs from 7 companies in 17 trials: 12 Phase 2, 3 Phase 4, 1 Phase 1, 1 Phase 3; Metabolic and endocrine, Other, Psychiatry; next expected readout Dec 2026.

G protein-coupled receptor for oxytocin (OXT), a neuropeptide hormone released by the posterior pituitary gland that plays a key role in social behavior and other biological processes, such as milk ejection. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as phospholipase C. OXTR is…. (UniProt, P30559)

Open in Phaseline: the race on OXTR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Yale UniversityOxytocin
Oxytocin receptor agonist
OXTRPhase 4Oxytocin; PainNov 2028
ACADIA PharmaceuticalsCarbetocin (ACP-101)
Oxytocin receptor agonist
OXTRPhase 3Hyperphagia in Prader-Willi Syndrome; Postpartum Hemorrhage–
University Hospital, Basel, SwitzerlandOxytocin
Oxytocin receptor agonist
OXTRPhase 2Arginine Vasopressin DeficiencyDec 2026
Massachusetts General HospitalOxytocin
Oxytocin receptor agonist
OXTRPhase 2Binge-eating Disorder; Obesity, AdolescentDec 2026
Elizabeth Austen LawsonOxytocin
Oxytocin receptor agonist
OXTRPhase 2Autism Spectrum Disorder; Vasopressin DeficiencyJun 2027
University of NebraskaOxytocin
Oxytocin receptor agonist
OXTRPhase 2StressNov 2027
University Hospital, Basel, SwitzerlandIntranasal OXT (Syntocinon®)
Oxytocin receptor agonist
OXTRPhase 2Central Diabetes Insipidus (cDI)–
Memorial University of NewfoundlandOxytocin
Oxytocin receptor agonist
OXTRPhase 2Chronic Pain–

Conditions

Pain (2) Arginine Vasopressin Deficiency (2) Chronic Pain (2) Stress (2) Postpartum Hemorrhage (2) Oxytocin (1) Autism Spectrum Disorder (1) Vasopressin Deficiency (1) Central Diabetes Insipidus (cDI) (1) Binge-eating Disorder (1) Obesity, Adolescent (1) Hyperphagia in Prader-Willi Syndrome (1)

Modalities

small molecule (8)

Companies

University Hospital, Basel, Switzerland (2) Yale University (1) Elizabeth Austen Lawson (1) Massachusetts General Hospital (1) Memorial University of Newfoundland (1) University of Nebraska (1) ACADIA Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.